Put Options

15 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$114.58 - $153.15 $8.69 Million - $11.6 Million
75,800 New
75,800 $8.73 Million
Q1 2022

May 17, 2022

BUY
$72.45 - $94.81 $3.82 Million - $5 Million
52,700 Added 21.73%
295,200 $27.7 Million
Q4 2021

Feb 15, 2022

BUY
$79.65 - $106.22 $5.92 Million - $7.89 Million
74,300 Added 44.17%
242,500 $20.7 Million
Q3 2021

Nov 16, 2021

BUY
$86.18 - $99.03 $12 Million - $13.8 Million
139,700 Added 490.18%
168,200 $16.1 Million
Q2 2021

Aug 16, 2021

SELL
$89.43 - $102.27 $2.3 Million - $2.63 Million
-25,700 Reduced 47.42%
28,500 $2.77 Million
Q1 2021

May 18, 2021

SELL
$87.57 - $119.4 $455,363 - $620,880
-5,200 Reduced 8.75%
54,200 $5.27 Million
Q4 2020

Feb 17, 2021

BUY
$86.91 - $108.33 $1.27 Million - $1.58 Million
14,600 Added 32.59%
59,400 $5.69 Million
Q3 2020

Nov 17, 2020

BUY
$96.16 - $135.15 $2.29 Million - $3.22 Million
23,800 Added 113.33%
44,800 $4.31 Million
Q2 2020

Aug 17, 2020

BUY
$85.09 - $130.36 $1.52 Million - $2.33 Million
17,900 Added 577.42%
21,000 $2.56 Million
Q1 2020

May 15, 2020

SELL
$75.11 - $113.76 $796,166 - $1.21 Million
-10,600 Reduced 77.37%
3,100 $268,000
Q4 2019

Feb 14, 2020

BUY
$86.8 - $118.57 $902,720 - $1.23 Million
10,400 Added 315.15%
13,700 $1.47 Million
Q3 2019

Nov 14, 2019

BUY
$83.82 - $101.5 $83,820 - $101,500
1,000 Added 43.48%
3,300 $297,000
Q1 2019

May 16, 2019

SELL
$69.31 - $91.53 $62,379 - $82,377
-900 Reduced 28.13%
2,300 $203,000
Q4 2018

Feb 15, 2019

SELL
$68.32 - $124.36 $116,143 - $211,412
-1,700 Reduced 34.69%
3,200 $229,000
Q3 2018

Nov 14, 2018

BUY
$98.88 - $125.85 $484,512 - $616,665
4,900 New
4,900 $602,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.